Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 235-240

  Bartelink, Imke H ^a   Wolfs, Tom ^a   Jonker, Martine ^a   De Waal, Marjolein ^a   Egberts, Toine C G ^a,b   Ververs, Tessa T ^a   Boelens, Jaap J ^a   Bierings, Marc ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INVASIVE ASPERGILLOSIS; LIVER TOXICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; URTICARIA;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84872028587     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01540-12     Document Type: Article

References (18)

1. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E. 2005. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106:2641-2645.
2. Schwartz S, Reisman A, Troke PF. 2011. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection 39:201-210.
3. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. 2006. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin. Infect. Dis. 43:1449-1455.
4. Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A. 2011. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr. Infect. Dis. J. 30:533-534.
5. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
6. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21:240-248.
7. Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, Mauz-Körholz C, Preiss R. 2010. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob. Agents Chemother. 54:3225-3232.
8. Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I. 2010. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob. Agents Chemother. 54:4116-4123.
9. Karlsson MO, Lutsar I, Milligan PA. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53:935-944.
10. Pfizer Limited. 2012. Vfend summary of product information. Pfizer Limited, London, United Kingdom.
11. Shima H, Miharu M, Osumi T, Takahashi T, Shimada H. 2010. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr. Blood Cancer 54:1050-1052.
12. Bruggemann RJ, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens NM, Mouton JW, Verweij PE, Burger DM. 2008. Therapeutic drug monitoring of voriconazole. Ther. Drug Monit. 30:403-411.
13. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
14. Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. 2010. Voriconazole therapeutic drug monitoring: focus on safety. Expert. Opin. Drug Saf. 9:125-137.
15. Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH. 2012. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J. Antimicrob. Chemother. 67:2717-2724.
16. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55:4782-4788.
17. Meletiadis J, Mavridou E, Melchers WJ, Mouton JW, Verweij PE. 2012. Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob. Agents Chemother. 56:2524-2529.
18. Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans M, Meyfroidt G, de Hoon J, Verbesselt R, Willems L. 2011. Voriconazole plasma levels in children are highly variable. Eur. J. Clin. Microbiol. Infect. Dis. 30:283-287.